argenx is expected to report Q4 2025 revenue of $1.29 billion and EPS of $6.20, with the current stock price of $840.28 trailing the average analyst target of $986.78.
Investors are primarily focused on the commercial momentum of Vyvgart, specifically its launch trajectory in the chronic inflammatory demyelinating polyneuropathy (CIDP) market following recent regulatory approvals.
Strong global adoption in myasthenia gravis has already propelled triple-digit year-over-year revenue growth throughout 2025. Market participants are also monitoring the company's pipeline execution and leadership transition as it targets significant patient expansion goals through 2030.